These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28758825)

  • 1. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Papin A; Le Gouill S; Chiron D
    Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies.
    Burger JA; Ford RJ
    Semin Cancer Biol; 2011 Nov; 21(5):308-12. PubMed ID: 21945516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
    Chen Z; Teo AE; McCarty N
    Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in mantle cell lymphoma.
    Tucker D; Rule S
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):491-506. PubMed ID: 28480764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.
    Papin A; Tessoulin B; Bellanger C; Moreau A; Le Bris Y; Maisonneuve H; Moreau P; Touzeau C; Amiot M; Pellat-Deceunynck C; Le Gouill S; Chiron D
    Leukemia; 2019 Oct; 33(10):2442-2453. PubMed ID: 30940906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
    Zhang H; Chen Z; Neelapu SS; Romaguera J; McCarty N
    Oncotarget; 2016 Mar; 7(12):14350-65. PubMed ID: 26885608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma in relapse: the role of emerging new drugs.
    Diefenbach CS; O'Connor OA
    Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
    Klener P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
    Lantermans HC; Minderman M; Kuil A; Kersten MJ; Pals ST; Spaargaren M
    Leukemia; 2021 Mar; 35(3):881-886. PubMed ID: 32591642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies.
    Qualls D; Kumar A; Epstein-Peterson ZD
    Leuk Lymphoma; 2022 Nov; 63(11):2515-2527. PubMed ID: 35704674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mantle cell lymphoma-management in evolution.
    Rajguru S; Kahl BS
    Chin Clin Oncol; 2015 Mar; 4(1):8. PubMed ID: 25841715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
    Chiron D; Bellanger C; Papin A; Tessoulin B; Dousset C; Maiga S; Moreau A; Esbelin J; Trichet V; Chen-Kiang S; Moreau P; Touzeau C; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2016 Dec; 128(24):2808-2818. PubMed ID: 27697772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents in mantle cell lymphoma.
    Kumar A
    Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
    Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into Mantle Cell Lymphoma Pathobiology, Diagnosis, and Treatment Using Network-Based and Drug-Repurposing Approaches.
    Orfanoudaki G; Psatha K; Aivaliotis M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.